Pharmaceutical News RSS Feed - Pharmaceutical News

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]

Global Generic Drugs market to grow at 11.02% CAGR over 2013-2018

Global Information Inc. announces the addition of a new market research report "Global Generic Drugs Market 2014-2018" at GIIResearch.com [More]
Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

Cubist Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI). [More]

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. [More]

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). [More]

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). [More]

Children get codeine in U.S. emergency rooms, despite risks: Study

Despite its potentially harmful effects in children, codeine continues to be prescribed in U.S. emergency rooms, according to new research from UCSF Benioff Children's Hospital San Francisco. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Benzodiazepines may contribute to respiratory problems in people with COPD

Benzodiazepines may contribute to respiratory problems in people with COPD

A group of drugs commonly prescribed for insomnia, anxiety and breathing issues "significantly increase the risk" that older people with chronic obstructive pulmonary disease, or COPD, need to visit a doctor or Emergency Department for respiratory reasons, new research has found. [More]
Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells. [More]
Survey finds counterfeit and defective emergency contraceptives in Peru

Survey finds counterfeit and defective emergency contraceptives in Peru

A survey of emergency contraceptive pills in Peru found that 28 percent of the batches studied were either of substandard quality or falsified. Many pills released the active ingredient too slowly. Others had the wrong active ingredient. One batch had no active ingredient at all. [More]
Sprifermin reduces cartilage loss in patients with knee osteoarthritis

Sprifermin reduces cartilage loss in patients with knee osteoarthritis

In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. [More]
Probiotics usage proves ineffective for infant colic symptoms

Probiotics usage proves ineffective for infant colic symptoms

​Colic affects about one in five infants in the United States annually and accounts for numerous pediatric visits during the first several months after birth. [More]
Drug used to treat TB may also act against various infections, says study

Drug used to treat TB may also act against various infections, says study

A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a study by University of Illinois chemists and collaborators. [More]

Study shows sprifermin reduces cartilage thickness loss in patients with knee osteoarthritis

In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. [More]

Researchers discover that anti-seizure drug reduces alcohol consumption

Boston-Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug and Alcohol Abuse, may lead to more effective treatments for alcoholism. [More]
Adrenaline does not boost long-term survival rates in heart attack patients, says study

Adrenaline does not boost long-term survival rates in heart attack patients, says study

Giving patients adrenaline after they suffer a cardiac arrest outside of a hospital does not increase their prospects of surviving long-term, according to new research conducted at St. Michael's Hospital. [More]

Docs who treat patients with severe LAM face agonizing treatment decision

​Doctors who treat patients with a severe and progressive respiratory disease called lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. [More]

Findings could revive use of chloroquine drug in treating, preventing mosquito-bourne disease

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently. [More]